Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (16 September 2017)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.

Australian applications

Here are the 108 PCT patent applications relevant to Australia's Life Sciences sector that have published since the start of 2017, for a publication rate of 2.8 applications per week:

WO/2017/160587, Neutralizing monoclonal antibodies to Il-25 and uses thereof, Abeome Corporation (US) with Nathan Bartlett and others
WO/2017/156591, Osteoarthritis miRNAs, Murdoch Childrens Research Institute, 21 September 2017
WO/2017/156580, Colony forming medium and use thereof, Cynata Therapeutics, 21 September 2017
WO/2017/153521, Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153520, Benzopiperidine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 4 September 2017
WO/2017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153518, PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153515, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153513, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/152237, Novel analogues of Desferrioxamine B (DFOB), University of Sydney, 14 September 2017
WO/2017/147654, Use of phosphorylated tau and p38gamma to treat a neurological condition, Newsouth Innovations Pty Ltd, 8 September 2017
WO/2017/147653, Methods of treating bone diseases, disorders and/or injuries and reagents therefor, Cellmid Ltd, 8 September 2017
WO/2017/147649, Methods of treatment, Magellan Stem Cells Pty Ltd, 8 September 2017
WO/2017/143406, Multi-specific molecules, Imunexus Pty Ltd, 31 August 2017
WO/2017/143397, Inhibitors of β-arrestin-neurokinin 1 receptor interactions for the treatment of pain, Monash University, 31 August 2017
WO/2017/142825, N3-substituted iminopyrimidinones as antimalarial agents, Merck Sharp & Dohme Corp, 24 August 2017
WO/2017/142821, Compounds for the treatment of malaria, Merck Sharp & Dohme Corp, 24 August 2017
WO/2017/139854, Compositions and methods for the treatment of sinus disease and disorders, ENT Technologies Pty Ltd, 24 August 2017
WO/2017/139849, Anti-virus agent and method for treatment of viral infection, Recce Ltd, 24 August 2017
WO/2017/139846, Formulation and method of use, ATP Institute Pty Ltd, 24 August 2017
WO/2017/139845, Novel alpha conotoxin peptides, University of Queensland, 24 August 2017
WO/2017/139290, Tralokinumab delivery device, Medimmune, 17 August 2017
WO/2017/136871, Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/136870, Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/132728, Proteinaceous compounds and uses therefor, University of Canberra, 10 August 2017
WO/2017/127892, Cancer treatment, Propanc Pty Ltd, 3 August 2017
WO/2017/124156, Compositions that brighten skin, provide sun protection, and permit Vitamin D production, Ernest Armstong, 27 July 2017
WO/2017/124147, Novel biomolecule conjugates and uses therefor, The University of Western Australia, 27 July 2017
WO/2017/117631, Mutated truncated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117630, Mutated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117627, Drug release device and use, Jurox Pty Ltd, 13 July 2017
WO/2017/112792, Tripartite modulators of endosomal G Protein-Coupled Receptors, Takeda Pharmaceutical Company Ltd, 29 June 2017
WO/2017/106930, Compounds, Commonwealth Scientific and Industrial Research Organisation, 29 June 2017
WO/2017/106926, Nucleic acid oligomers and uses therefor, Queensland University of Technology, 29 June 2017
WO/2017/106899, Therapeutic methods using erythrocytes, Sangui Bio Pty Ltd, 29 June 2017
WO/2017/100863, Injectable composition and a method of treatment of the physical addiction, Verita Research Pte Ltd, 22 June 2017
WO/2017/100861, Inhibition of cytokine-induced SH2 protein in NK cells, Walter and Eliza Hall Institute of Medical Research, 22 June 2017
WO/2017/100860, Exfoliant bar, DPP Pharmaceuticals Pty Ltd, 22 June 2017
WO/2017/100858, Polymer composite for controlled release of an agent, Commonwealth Scientific and Industrial Research Organisation, 22 June 2017
WO/2017/100849, 6-oxopurine phosphoribosyl transferase inhibitors, University of Queensland, 22 June 2017
WO/2017/100825, A pharmaceutical composition and uses therefor, Robert Gilligan, 22 June 2017
WO/2017/100819, Modular syntheses of discoipyrrole type alkaloids and analogues, Australian National University, 22 June 2017
WO/2017/096432, Immunomodulating composition for treatment, Admedus Vaccines Pty Ltd, 15 June 2017
WO/2017/096431, Proteinaceous molecules and methods of use, University of Queensland, 15 June 2017
WO/2017/096430, Hydroxamic acid-based compounds, University of Sydney, 15 June 2017
WO/2017/096427, Pharmaceutical formulation, Phosphagenics Ltd, 15 June 2017
WO/2017/096426, Methods and compositions for treating gastric ulcers, Luoda Pharma Pty Ltd, 15 June 2017
WO/2017/093807, Methods of treating or alleviating mental disorders and associated symptoms, Florey Institute of Neuroscience and Mental Health, 8 June 2017
WO/2017/091866, Regulation of cytokine production, Commonwealth Scientific and Industrial Research Organisation, 8 June 2017
WO/2017/091850, Novel anti-angiogenic fusion polypeptides, Pieris Australia Pty Ltd, 8 June 2017
WO/2017/088031, Photostable compounds, absorbing compounds and uses thereof, Commonwealth Scientific and Industrial Research Organisation, 1 June 2017
WO/2017/088028, CD131 binding proteins and uses thereof, CSL Ltd, 1 June 2017
WO/2017/088027, Inhibin analogs, Hudson Institute Of Medical Research, 1 June 2017
WO/2017/088018, Production of viruses in cell culture, Commonwealth Scientific and Industrial Research Organisation, 1 June 2017
WO/2017/088012, Genetically modified cells and uses thereof, Cartherics Pty Ltd, 1 June 2017
WO/2017/083938, Method of controlled competitive exchange, Anteo Technologies Pty Ltd, 26 May 2017
WO/2017/083931, A non-surgical vulvovaginal rejuvenation technique and an injecting device therefor, Abbas Al-Taiff, 26 May 2017
WO/2017/083925, Compounds and methods for treating metabolic disorders, Garvan Institute of Medical Research, 26 May 2017
WO/2017/083914, Compounds for medicinal applications, Australian Biomedical Co. Pty Ltd, 26 May 2017
WO/2017/079802, Proenzyme composition, Propanc Pty Ltd, 18 May 2017
WO/2017/078928, FXR agonists and methods for making and using, Salk Institute for Biological Studies, 11 May 2017
WO/2017/078927, Analogs of fexaramine and methods of making and using, Salk Institute for Biological Studies, 11 May 2017
WO/2017/075672, Method and product for testing response to oral glucose load, INR Enterprises Pty Ltd, 11 May 2017
WO/2017/075670, Mobilizing leukemia cells, Children's Hospital Los Angeles (US) with Antisense Therapeutics, 11 May 2017
WO/2017/075661, Methods and compositions for treating CNS injury, Monash University, 11 May 2017
WO/2017/075653, Chlamydia antigens and uses thereof, University of the Sunshine Coast, 11 May 2017
WO/2017/070752, Imaging agents, University of Queensland, 4 May 2017
WO/2017/070744, Methods and compositions for improving glucose metabolism, Monash University, 4 May 2017
WO/2017/070738, A method of treatment and agents useful for same, University of Queensland, 4 May 2017
WO/2017/070735, Liposomal vaccine, Griffith University, 4 May 2017
WO/2017/070731, Compositions and methods for the treatment of Alzheimer's disease, Innate Immunotherapeutics Ltd, 4 May 2017
WO/2017/066827, Methods of reducing mammographic breast density and/or breast cancer risk, Havah Therapeutics Pty Ltd, 27 April 2017
WO/2017/063023, Compositions and methods for the treatment of diseases involving mucin, Newsouth Innovations Pty Ltd, 20 April 2017
WO/2017/063017, Treatment or prevention of giardiasis with a biologically active extract from Terminalia ferdinandiana fruit, Paran Rayan, 20 April 2017
WO/2017/059486, Compositions and methods for the treatment of epilepsy, Innate Immunotherapeutics Ltd, 13 April 2017
WO/2017/059485, Compositions and methods for protection and/or repair of the nervous system, Innate Immunotherapeutics Ltd, 13 April 2017
WO/2017/059319, Combination therapy of bromodomain inhibitors and checkpoint blockade, Dana-Farber Cancer Institute (US) and Peter MacCallum Cancer Institute, 6 April 2017
WO/2017/054047, Antimicrobial polymyxin derivative compounds, Monash University, 6 April 2017
WO/2017/054042, Novel formulation and treatment methods, University of Queensland, 6 April 2017
WO/2017/049349, A method of treatment and prophylaxis, Hudson Institute of Medical Research, 30 March 2017
WO/2017/045034, Ubiquinone and ubiquinol compositions, and methods relating thereto, Pharmako Biotechnologies Pty Ltd, 23 March 2017
WO/2017/045019, Antibiotic therapy, Boulos & Cooper Pharmaceuticals Pty Ltd, 23 March 2017
WO/2017/041142, Polymer conjugate comprising a bioactive agent, Polyactiva Pty Ltd, 16 March 2017
WO/2017/041139, Lymph directing prodrugs, Monash University, 16 March 2017
WO/2017/041133, Cell expansion methods and therapeutic compositions, Cell Ideas Pty Ltd, 16 March 2017
WO/2017/035595, Formation of bone, Elastagen Pty Ltd, 9 March 2017
WO/2017/035587, Bioactive polymer for bone regeneration, University of Sydney, 9 March 2017
WO/2017/035582, Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins, University of Adelaide, 9 March 2017
WO/2017/035566, Plasma polymerised oxazoline coatings and uses thereof, University of South Australia, 9 March 2017
WO/2017/031299, Enzymatic fractions with anti-inflammatory activity, Anatara Lifesciences Ltd, 23 February 2017
WO/2017/030901, Mycoplasma bovis compositions, Zoetis (US) with University of Melbourne, 23 February 2017
WO/2017/027910, Connexin 45 inhibition for therapy, University of Sydney, 23 February 2017
WO/2017/027898, Novel cancer treatment involving modulation of Il-3 activity, University of South Australia, 23 February 2017
WO/2017/025635, Composition for the treatment of joint conditions, Bertrand Stoffel, 16 February 2017
WO/2017/024355, Compositions comprising S1P receptor modulators, Akaal Pharma Pty Ltd, 16 February 2017
WO/2017/020094, Methods for treating tumours, Centenary Institute of Cancer Medicine and Cell Biology, 9 February 2017
WO/2017/020087, Emollient composition, Eupharma Pty Ltd, 9 February 2017
WO/2017/020086, Benzodiazepines as bromodomain inhibitors, Catalyst Therapeutics Pty Ltd, 9 February 2017
WO/2017/020065, n-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds, University of South Australia, 9 February 2017
WO/2017/017511, Modified release formulation for treating premature ejaculation, Selim Kameel, 2 February 2017
WO/2017/015722, Complexes for intracellular imaging, University of South Australia, 2 February 2017
WO/2017/015720, Fibrotic treatment, Monash University, 2 February 2017
WO/2017/015703, Antiseptic polymer and synthesis thereof, University of Sydney, 2 February 2017
WO/2017/011863, Neuroprotective agents derived from spider venom peptides, University of Queensland, 26 January 2017
WO/2017/008101, Novel aminopeptidase inhibitors and methods of use, Monash University, 19 January 2017
WO/2017/004678, Cross-reactive antifungal adoptive T cell therapy, University of Sydney, 12 January 2017
WO/2017/004674, Therapeutic compounds and compositions for treating social disorders and substance use disorders, University of Sydney, 12 January 2017
WO/2017/004672, Peptidyl TPOR antagonists and uses thereof, Polymers CRC Ltd, 12 January 2017

New Zealand applications

Here are the 15 PCT patent applications relevant to New Zealand's Life Sciences sector that have published since the start of 2017, for a publication rate of 0.4 applications per week:

WO/2017/153943, Topical composition, Biopharm NZ Ltd, 14 September 2017
WO/2017/142424, Treatment of neurodegenerative disorders, Garth Cooper, 24 August 2017
WO/2017/131534, Treatment of vascular anomalies, Gillies McIndoe Research Institute, 3 August 2017
WO/2017/111618, Infant formula comprising human milk peptides, A2 Milk Company Ltd, 29 June 2017
WO/2017/099612, Marker compounds of Leptospermum honeys and methods of isolation and assaying thereof, Comvita Ltd, 15 June 2017
WO/2017/095237, Carbon monoxide releasing norbornenone compounds, Ivan Sammut, 8 June 2017
WO/2017/082753, Glycolipid compounds and their uses in the treatment of tumours, Agalimmune Ltd, 18 May 2017
WO/2017/078544, Nutrient loss reduction method, PGG Wrightson Seeds Ltd, 11 May 2017
WO/2017/074262, Core-shell composite material, Agency for Science, Technology and Research, 4 May 2017
WO/2017/065619, Nitrogen utilisation modulation, PGG Wrightson Seeds Ltd, 20 April 2017
WO/2017/061878, Antimicrobial gel containing silver nanoparticles, Carla Meledandri, 13 April 2017
WO/2017/034420, Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) and their use in therapy, Auckland Uniservices Ltd, 2 March 2017
WO/2017/034418, Acoustic driven drug delivery systems, John Reynolds, 2 March 2017
WO/2017/018889, Manuka and/or kanuka honey wet wipes and manuka and/or kanuka oil tissues, Imbue NZ Ltd, 2 February 2017
WO/2017/003305, Peptides and uses thereof, Auckland Uniservices Ltd, 5 January 2017